1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Drug Delivery - Innovations, trends, and their impact on pharma

Why you need Drug Delivery - Innovations, trends, and their impact on pharma

Revolutionary changes are disrupting the status quo simply through developments in the way drugs are given to patients. In a rapidly evolving field, drug delivery systems are offering growth opportunities and solutions – as well as presenting difficulties – as the range of choices grows.

To make sure you don't get left behind you need to understand what is happening at the cutting edge from experts innovating and leading the way through the technological and regulatory minefield. See how companies like Sanofi, Surefire Medical and Invion among other market leaders explain how they see the market and how they are dealing with the challenges.

Top Takeaways:

Change is accelerating. There's a wide range of new products at late-stage development, 200+ partnership deals are signed each year and device companies are now entering the market directly
Reliance on delivery mechanisms is increasing as health economics requirements on efficacy and cost-effectiveness multiply
Significant delivery mechanism opportunities still exist with the potential to solve unmet needs with new formulations
Drug combinations offer risks and rewards – the promise of innovative formulas is potentially hampered by technology and regulation
Product franchises are protected by differentiating products and by extending a profitable drug's lifecycle
Opportunities are growing in new markets as the Far East opens up and China expands healthcare to the wider population

Key Issues Explored

Key drivers and how devices are transforming the market including oral medicines, inhalers, injectable devices, patches, subdermal implants, neurostimulation and smart devices
The challenges faced in choosing and developing the right delivery system and formulations, looking at biopharmaceuticals, biologics, excipients, large and small molecules, peptides, proteins and biosimilars
Hurdles to commercialisation globally – how companies are evolving strategies to deal with local regulatory issues for global products
Improving patient compliance with better outcomes and the potential for home-based care offered by some systems
The value of overcoming technical challenges before clinical trials begin
The cost-benefit considerations of different development models including outsourcing, partnerships and internal development.
The impact of health economics on innovation in the drug delivery market, reimbursement concerns and access issues

Who needs this report?

Presidents and VPs of product development – to see the drugs and devices in the pipeline and the potential opportunities and risks involved
Business development directors – to get support and improve and refine strategic direction and decisions
Device development team managers – to see expansion possibilities and the current state of the competitive market
Delivery and formulation specialists – to analyse current best practice
Manufacturers of devices – to see the top drug delivery partnerships and get an overview of growth prospects
Insurers and payers – to gain insights into the value of more effective delivery mechanisms to ensure the best use of limited resources
Big data companies and electronic health companies – to see current and future developments in connected devices


Director, Drug Delivery Technologies, European Pharma Company,
Vice President, Medical Device Development, Global pharma Company
Igor Gonda: President & CEO, Aradigm Corporation [Linkedin]
Jeff Macdonald: Senior Director, Corporate Communications, Acorda Therapeutics
Seth Yakatan: CSO, Vice President of Business Development, Invion Group
Director, Corporate Development, Respiratory Product Development Company
Director, Pharmaceutical Sciences, Respiratory Product Development Company Douglas Marenzi: CEO, PHC Technologies
David Urquhart: Business Development, PHC Technologies
Morten Nielsen: CEO, Medicom Innovation Partner
Frédéric Gabriel: CSO and General Manager, Haselmeier
Jim Chomas Ph.D: President and CEO, Surefire Medical
Norman Weldon: Chairman, SureFire Medical
Julian Chick, Ph.D: COO, Admedus Ltd
JP Errico, Ph.D: CEO, electroCore Medical

Table Of Contents

Drug Delivery - Innovations, trends, and their impact on pharma
1Executive Summary
2Research Objectives
3Research Methodology
4Setting the scene
41Over a third of approved drugs rely on advanced drug delivery systems
42Advanced drug delivery solutions at the heart of drug development
43Oral delivery the number one route of delivery?44Injectables remain the main route for biopharmaceuticals
45Significant investment activity in diabetes, ocular diseases and CNS?46Single inhaler combination devices expand utility and keep generics at bay
5Role of drug delivery 25
51Key insights
52Drug delivery technologies have transformed medicine
53Delivery driven by pharma
54Role 1: Improve patient adherence and compliance
55Role 2: Improve product lifecycle management
56Role 3: Increase market access
6Challenges of developing drug combinations
61Key insights
62Regulatory challenges
63Health economics Technical challenges
7Recent innovations in Drug Delivery
71Key insights?72Non-injectable biopharmaceuticals take centre stage
73Next step pulmonary delivery of proteins?74Smart inhalers improve patient compliance
8Co-development of drug devices
81Key insights?82Three pronged approach to drug development
83Companies have to take risks to innovate
84Partnerships are a two way street
9Future opportunities
91Key insights?92Connected devices add value?93Self-regulating devices control long-term release Non-invasive devices address unmet needs
10Conclusions Appendix

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Laboratory Products Purchasing Trends, 2016–2017

Global Laboratory Products Purchasing Trends, 2016–2017

  • $ 6000
  • Industry report
  • December 2016
  • by Frost & Sullivan

An End-user Perspective on the Purchasing Process, Product Budgets, and Top Companies for Laboratory Products Readers of Lab Manager Magazine were invited to participate in an online survey in July 2016. ...

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.